Distant metastasis in triple-negative breast cancer

Neoplasma

Volumn 60, Issue 3, 2013, Pages 290-294

  Tseng, L M ^a,b   Hsu, N C ^c   Chen, S C ^d   Lu, Y S ^e   Lin, C H ^e   Chang, D Y ^e   Li, H ^f   Lin, Y C ^d,g   Chang, H K ^d,g   Chao, T C ^a   Ouyang, F ^h   Hou, M F ^h,i,j  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

^g CHANG GUNG UNIVERSITY   (Taiwan)

^h KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^j KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

more..

Author keywords

Metastasis; Survival; Triple negative breast cancer

Indexed keywords

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; DISTANT METASTASIS; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIDDLE AGED; OVERALL SURVIVAL; PLEURA METASTASIS; TRIPLE NEGATIVE BREAST CANCER; AGED; BONE TUMOR; BRAIN TUMOR; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

MLCS; MLOWN;

EID: 84879343177     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_038     Document Type: Article

References (23)

1. PEROU CM, SORLIE T, EISEN MB, VAN DE RIJN M, JEFFREY SS et al: Molecular portraits of human breast tumours. Nature 2000; 406: 747-752. http://dx.doi.org/10.1038/35021093
2. SORLIE T, TIBSHIRANI R, PARKER J, HASTIE T, MARRON JS et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 8418-8423.
3. CHANG HY, NUYTEN DS, SNEDDON JB, HASTIE T, TIBSHIRANI R et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 3738-3743. http://dx.doi.org/10.1073/pnas.0409462102
4. NAUME B, ZHAO X, SYNNESTVEDT M, BORGEN E, RUSSNES HG et al: Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Molecular oncology 2007; 1: 160-171. http://dx.doi.org/10.1016/j.molonc.2007.03.004
5. CAREY LA, DEES EC, SAWYER L, GATTI L, MOORE DT et al: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334. http://dx.doi.org/10.1158/1078-0432.CCR-06-1109
6. LIEDTKE C, MAZOUNI C, HESS KR, ANDRE F, TORDAI A et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281. http://dx.doi.org/10.1200/JCO.2007.14.4147
7. DENT R, TRUDEAU M, PRITCHARD KI, HANNA WM, KAHN HK et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434. http://dx.doi.org/10.1158/1078-0432.CCR-06-3045
8. HAFFTY BG, YANG Q, REISS M, KEARNEY T, HIGGINS SA et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-5657. http://dx.doi.org/10.1200/JCO.2006.06.5664
9. KREIKE B, VAN KOUWENHOVE M, HORLINGS H, WEIGELT B, PETERSE H et al: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65. http://dx.doi.org/10.1186/bcr1771
10. PAL SK, MORTIMER J: Triple-negative breast cancer: novel therapies and new directions. Maturitas 2009; 63: 269-274. http://dx.doi.org/10.1016/j.maturitas.2009.06.010
11. YAMAMOTO Y, IWASE H: Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010; 15: 341-351. http://dx.doi.org/10.1007/s10147-010-0106-1
12. PODO F, BUYDENS LM, DEGANI H, HILHORST R, KLIPP E et al: Triple-negative breast cancer: present challenges and new perspectives. Molecular oncology 2010; 4: 209-229. http://dx.doi.org/10.1016/j.molonc.2010.04.006
13. RAKHA EA, REIS-FILHO JS, ELLIS IO: Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-2581. http://dx.doi.org/10.1200/JCO.2007.13.1748
14. KASSAM F, ENRIGHT K, DENT R, DRANITSARIS G, MYERS J et al: Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009; 9: 29-33. http://dx.doi.org/10.3816/CBC.2009.n.005
15. MAKI DD, GROSSMAN RI: Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol 2000; 21: 1064-1066.
16. TSUDA H, TAKARABE T, HASEGAWA F, FUKUTOMI T, HIROHASHI S: Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000; 24: 197-202. http://dx.doi.org/10.1097/00000478-200002000-00005
17. HICKS DG, SHORT SM, PRESCOTT NL, TARR SM, COLEMAN KA et al: Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006; 30: 1097-1104. http://dx.doi.org/10.1097/01.pas.0000213306.05811.b9
18. ALBIGES L, ANDRE F, BALLEYGUIER C, GOMEZ-ABUIN G, CHOMPRET A et al: Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol 2005; 16: 1846-1847. http://dx.doi.org/10.1093/annonc/mdi351
19. FULFORD LG, REIS-FILHO JS, RYDER K, JONES C, GILLETT CE et al: Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007; 9: R4. http://dx.doi.org/10.1186/bcr1636
20. RODRIGUEZ-PINILLA SM, SARRIO D, HONRADO E, HARDISSON D, CALERO F et al: Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006; 12: 1533-1539. http://dx.doi.org/10.1158/1078-0432.CCR-05-2281
21. DENT R, HANNA WM, TRUDEAU M, RAWLINSON E, SUN P et al: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009; 115: 423-428. http://dx.doi.org/10.1007/s10549-008-0086-2
22. CAREY LA, PEROU CM, LIVASY CA, DRESSLER LG, COWAN D et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502. http://dx.doi.org/10.1001/jama.295.21.2492
23. BANERJEE S, REIS-FILHO JS, ASHLEY S, STEELE D, ASHWORTH A et al: Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 2006; 59: 729-735. http://dx.doi.org/10.1136/jcp.2005.033043